FORTRESS BIOTECH

Company Overview

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana Farber Cancer Center and Sentynl Therapeutics.

Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Nov 13 2026, 8:00 AM EST

Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Nov 12 2026, 4:01 PM EST

Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Nov 10 2026, 4:05 PM EST

Stock Overview

Symbol	FBIO
Exchange	Nasdaq
Market Cap	62.7m
Last Price	$1.88
52-Week Range	$1.75 - $4.53

11/13/2026 09:00 PM EST

Investor Relations

Jaclyn Jaffe
Nicole McCloskey
T: 781-652-4500
ir@fortressbiotech.com

Management Team

Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive Officer

Michael S. Weiss
Executive Vice Chairman, Strategic Development

David Jin
Chief Financial Officer and Head of Corporate Development

Fortress Biotech, Inc.

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.